Program Overview
In this module, Jonathan Loree, MD, MS, along with Scott Kopetz, MD, PhD, course chair, will first provide a brief overview of the history and prevalence of colorectal cancer, as well as best practices for screening. Following, the expert faculty will review the role of clinically relevant biomarkers in metastatic colorectal cancer. Strategies for detecting and managing various prevalent mutations will be reviewed in the context of current guidelines. Upon completion of this 30-minute module, learners will be equipped with information to better detect and treat their patients with colorectal cancer.
Target Audience
Community oncologists, oncologists, advanced practitioners, oncology nurses, and other healthcare professionals involved in the care of patients with colorectal cancer
Learning Objective
- Discuss disease biomarkers and genomic predictors of response to therapy for patients with colorectal cancer with a BRAF mutation
Faculty
Scott Kopetz, MD, PhD
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Jonathan Loree, MD, MS
Department of Medical Oncology
BC Cancer – Vancouver Centre
Vancouver, British Columbia, Canada
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
| Faculty | Relationship Identified With: |
| Scott Kopetz, MD, PhD | Consultant/Advisor: Amal Therapeutics; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer Health; Biocartis; Boehringer Ingelheim International GmbH; Boston Biomedical, Inc.; EMD Serono Inc.; Eli Lilly and Company; Genentech Inc.; Holy Stone Healthcare Co., Ltd.; Karyopharm Therapeutics; MedImmune; Merck & Co., Inc.; Navire Pharma; Novartis Pharmaceuticals Corporation; Pierre Fabre; Roche; Redx Pharma; Symphogen
Research/Grant Support: Amgen Inc.; Array BioPharma; Biocartis; Eli Lilly and Company; EMD Serono Inc.; Genentech, Inc.; Guardant Health; MedImmune; Novartis Pharmaceuticals Corporation; Roche; Sanofi Stock Option: MolecularMatch; Navire Pharma |
| Jonathan Loree, MD, MS | Consultant/Advisor: Amgen Inc.; Bayer Health; Eisai Co., Ltd.; Ipsen Biopharmaceuticals Canada Inc.; Novartis Pharmaceuticals Corporation; Purdue Pharma; Taiho Pharma Canada, Inc.
Research/Grant Support: Ipsen Biopharmaceuticals Canada Inc.Planners, Managers, Reviewers |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
AcademicCME designates this live material for a maximum of 0.50 AMA PRA Category 1 Credits TM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours, including 0.50 Pharmacotherapeutic Contact Hours (Provider Number P0491).
Financial Support
This activity has been supported by an independent educational grant from Pfizer Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Pfizer Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].
